fMallinckrodt Institute of Radiology Washington University School of Medicine, Saint Louis, Missouri. gNova Southeastern University, Fort Lauderdale, Florida. hMoffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, Florida; MSK-RADS (Bone) Committee. iMayo Clinic Florida, Jacksonville, Florida. jStritch School of Medicine Loyola University Chicago, Maywood, Illinois; Commission on Radiation Oncology. kUniversity of Texas Health Science Center, Houston, Texas; American Academy of Orthopaedic Surgeons. lBrigham & Women's Hospital & Harvard Medical School, Boston, Massachusetts; American Association of Neurological Surgeons/Congress of Neurological Surgeons. mMayo Clinic Florida, Jacksonville, Florida, Primary care physician. nUniversity of Virginia, Charlottesville, Virginia. oSUNY Downstate Health Sciences University, Brooklyn, New York. pMayo Clinic, Jacksonville, Florida; Commission on Nuclear Medicine and Molecular Imaging. qSpecialty Chair, University of Kentucky, Lexington, Kentucky. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final document by individual contributors or their respective organization. Reprint requests to: publications@acr.org Discussion of Procedures by Variant Variant 1: Malignant or aggressive primary musculoskeletal tumor. Initial staging. Evaluation for pulmonary metastasis. Approximately 20% of patients with primary extremity sarcomas will have or develop distant metastatic disease. Pulmonary metastases account for approximately 75% of all sarcoma metastases, with variations of incidence depending on tumor histology and grade [4,5].
Malignant or Aggressive Primary Musculoskeletal Tumor Staging And Surveillance PCAs. fMallinckrodt Institute of Radiology Washington University School of Medicine, Saint Louis, Missouri. gNova Southeastern University, Fort Lauderdale, Florida. hMoffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, Florida; MSK-RADS (Bone) Committee. iMayo Clinic Florida, Jacksonville, Florida. jStritch School of Medicine Loyola University Chicago, Maywood, Illinois; Commission on Radiation Oncology. kUniversity of Texas Health Science Center, Houston, Texas; American Academy of Orthopaedic Surgeons. lBrigham & Women's Hospital & Harvard Medical School, Boston, Massachusetts; American Association of Neurological Surgeons/Congress of Neurological Surgeons. mMayo Clinic Florida, Jacksonville, Florida, Primary care physician. nUniversity of Virginia, Charlottesville, Virginia. oSUNY Downstate Health Sciences University, Brooklyn, New York. pMayo Clinic, Jacksonville, Florida; Commission on Nuclear Medicine and Molecular Imaging. qSpecialty Chair, University of Kentucky, Lexington, Kentucky. The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through representation of such organizations on expert panels. Participation on the expert panel does not necessarily imply endorsement of the final document by individual contributors or their respective organization. Reprint requests to: publications@acr.org Discussion of Procedures by Variant Variant 1: Malignant or aggressive primary musculoskeletal tumor. Initial staging. Evaluation for pulmonary metastasis. Approximately 20% of patients with primary extremity sarcomas will have or develop distant metastatic disease. Pulmonary metastases account for approximately 75% of all sarcoma metastases, with variations of incidence depending on tumor histology and grade [4,5].